Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Ahlehoff

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Danish Medical Bulletin|November 4, 2011
Psoriasis and Cardiovascular Disease: epidemiological studiesOle Ahlehoff
Ugeskrift for Laeger|December 17, 2009
[Ranolazine--new treatment of chronic stable angina pectoris]Ole Ahlehoff, Peter Riis Hansen
Ugeskrift for Laeger|May 6, 2009
[Cardiovascular pharmacogenomics]Ole Ahlehoff, Peter Riis Hansen
Ugeskrift for Laeger|October 30, 2014
[Malignant melanoma with metastatic melanoma to the heart]Martin Frydland, Hanne Elming, Ole Ahlehoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 22, 2015
Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future PerspectivesJesper Lindhardsen, Søren Lund Kristensen, Ole Ahlehoff
International Journal of Dermatology|March 29, 2014
Cardiovascular aspects of psoriasis: an updated reviewOle Ahlehoff, Gunnar Gislason, Peter R Hansen
Archives of Dermatological Research|February 19, 2017
Psoriasis and cardiovascular events: updating the evidenceLine Raaby, Ole Ahlehoff, Annette de Thurah
International Journal of Cardiology|January 13, 2009
Anthracycline-induced cardiomyopathy: favourable effects of cardiac resynchronization therapyOle Ahlehoff, Anders M Galløe, Peter R Hansen
Ugeskrift for Laeger|July 27, 2010
[Psoriasis and atherothrombotic disease]Ole Ahlehoff, Gunnar H Gislason, Lone Skov, et al.
Lancet (London, England)|March 29, 2011
Risk assessment for recurrent venous thrombosisOle Ahlehoff, Gunnar Hilmar Gislasson, Christian Torp-Pedersen, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Danish Medical Bulletin|November 4, 2011
Psoriasis and Cardiovascular Disease: epidemiological studiesOle Ahlehoff
Ugeskrift for Laeger|December 17, 2009
[Ranolazine--new treatment of chronic stable angina pectoris]Ole Ahlehoff, Peter Riis Hansen
Ugeskrift for Laeger|May 6, 2009
[Cardiovascular pharmacogenomics]Ole Ahlehoff, Peter Riis Hansen
Ugeskrift for Laeger|October 30, 2014
[Malignant melanoma with metastatic melanoma to the heart]Martin Frydland, Hanne Elming, Ole Ahlehoff
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 22, 2015
Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future PerspectivesJesper Lindhardsen, Søren Lund Kristensen, Ole Ahlehoff
International Journal of Dermatology|March 29, 2014
Cardiovascular aspects of psoriasis: an updated reviewOle Ahlehoff, Gunnar Gislason, Peter R Hansen
Archives of Dermatological Research|February 19, 2017
Psoriasis and cardiovascular events: updating the evidenceLine Raaby, Ole Ahlehoff, Annette de Thurah
International Journal of Cardiology|January 13, 2009
Anthracycline-induced cardiomyopathy: favourable effects of cardiac resynchronization therapyOle Ahlehoff, Anders M Galløe, Peter R Hansen
Ugeskrift for Laeger|July 27, 2010
[Psoriasis and atherothrombotic disease]Ole Ahlehoff, Gunnar H Gislason, Lone Skov, et al.
Lancet (London, England)|March 29, 2011
Risk assessment for recurrent venous thrombosisOle Ahlehoff, Gunnar Hilmar Gislasson, Christian Torp-Pedersen, et al.
Pageof 7